Trials / Completed
CompletedNCT00330954
Gene Expression Profiling in Type 1 Diabetes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 64 (estimated)
- Sponsor
- Children's Mercy Hospital Kansas City · Academic / Other
- Sex
- All
- Age
- 7 Years – 14 Years
- Healthy volunteers
- Not accepted
Summary
One of the goals of the Kansas City Diabetes Consortium is to identify and characterize genes and their products that are associated with T1DM. Characterization of such genes and their products can aid in developing new tools for risk assessment, development of new prevention strategies and monitoring progression of disease. Study design: Descriptive, basic science pilot study. The results of this pilot study will be used to help design a much larger study to address the importance of viral response and autoimmune diabetes.
Detailed description
The hypothesis is that viral responsive genes are up-regulated prior to the onset of symptoms of Type 1 Diabetes (T1DM) and may correlate with increased expression of interferon alpha. Both genetic and environmental factors contribute to risk of development of T1DM. There are a number of conflicting reports associating viral infections and T1DM in genetically susceptible individuals and causality has not been proven. Viruses may not have a large role in the initiation of islet cell autoimmunity but more of a role in acceleration of the disease leading to overt symptoms. There are no studies describing viral responsive gene expression in these individuals.
Conditions
Timeline
- Start date
- 2006-06-01
- Completion
- 2008-04-01
- First posted
- 2006-05-29
- Last updated
- 2010-03-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00330954. Inclusion in this directory is not an endorsement.